chronic hepatitis B

Peer-Reviewed Publication Xia & He Publishing Inc. Background and objectives Peginterferon-α treatment exhibits low rates of the serological conversion rate of hepatitis B e antigen (HBeAg) and the negative conversion rate of hepatitis B virus (HBV) DNA, with significant myelosuppression leading to treatment discontinuation in some patients. Traditional Chinese medicine (TCM) may ameliorate liver inflammation […]

by Jia H. Jung edited by Sadie Harley, reviewed by Andrew Zinin Credit: Unsplash/CC0 Public Domain Liver specialist Maurizio Bonacini is in the race for a cure for hepatitis B, one of the world’s most widespread diseases and a top cause of liver cancer around the globe. “It’s the last frontier,” said Dr. Bonacini, a San Francisco-based